- Sweden
- /
- Medical Equipment
- /
- OM:ADDV A
Need To Know: Analysts Are Much More Bullish On ADDvise Group AB (publ) (STO:ADDV A) Revenues
ADDvise Group AB (publ) (STO:ADDV A) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's statutory forecasts. The revenue forecast for next year has experienced a facelift, with the analysts now much more optimistic on its sales pipeline.
After the upgrade, the dual analysts covering ADDvise Group are now predicting revenues of kr1.2b in 2023. If met, this would reflect a substantial 52% improvement in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of kr1.1b in 2023. It looks like there's been a clear increase in optimism around ADDvise Group, given the substantial gain in revenue forecasts.
See our latest analysis for ADDvise Group
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting ADDvise Group's growth to accelerate, with the forecast 40% annualised growth to the end of 2023 ranking favourably alongside historical growth of 21% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 22% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect ADDvise Group to grow faster than the wider industry.
The Bottom Line
The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for next year. They're also forecasting more rapid revenue growth than the wider market. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at ADDvise Group.
Analysts are clearly in love with ADDvise Group at the moment, but before diving in - you should be aware that we've identified some warning flags with the business, such as dilutive stock issuance over the past year. You can learn more, and discover the 2 other risks we've identified, for free on our platform here.
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:ADDV A
ADDvise Group
Supplies equipment to healthcare and research facilities in private and public sectors in Sweden, rest of Europe, North America, Africa, and Asia.
Undervalued moderate.